Merck & Company, Inc. (NYSE:MRK) – Equities research analysts at Jefferies Group issued their Q3 2017 earnings per share estimates for shares of Merck & in a research report issued on Monday, Zacks Investment Research reports. Jefferies Group analyst J. Holford anticipates that the company will post earnings per share of $1.03 for the quarter. Jefferies Group has a “Underperform” rating on the stock.
Merck & (NYSE:MRK) last issued its earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.08. The firm had revenue of $10.33 billion during the quarter, compared to analyst estimates of $10.54 billion. Merck & had a net margin of 11.60% and a return on equity of 27.08%. The business’s revenue was down 2.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.07 earnings per share.
TRADEMARK VIOLATION WARNING: This article was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/11/jefferies-group-comments-on-merck-company-inc-s-q3-2017-earnings-mrk.html.
Other equities analysts also recently issued reports about the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $73.00 target price (down from $74.00) on shares of Merck & in a report on Monday, July 24th. BidaskClub downgraded shares of Merck & from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Morgan Stanley downgraded shares of Merck & from an “overweight” rating to an “equal weight” rating and set a $56.00 target price for the company. in a report on Monday, October 30th. Credit Suisse Group reiterated an “outperform” rating and issued a $74.00 target price (down from $75.00) on shares of Merck & in a report on Tuesday, September 5th. Finally, UBS AG reduced their target price on shares of Merck & from $72.00 to $67.00 and set a “buy” rating for the company in a report on Monday, October 30th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $67.07.
Merck & (MRK) traded down $0.73 during mid-day trading on Thursday, hitting $55.48. The company had a trading volume of 16,743,801 shares, compared to its average volume of 9,494,131. The company has a market capitalization of $153,140.61, a P/E ratio of 14.45, a P/E/G ratio of 2.42 and a beta of 0.78. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.21. Merck & has a 12-month low of $54.41 and a 12-month high of $66.80.
A number of hedge funds and other institutional investors have recently modified their holdings of MRK. Fort Washington Investment Advisors Inc. OH boosted its position in Merck & by 133.4% in the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 144,247 shares of the company’s stock worth $9,165,000 after purchasing an additional 82,454 shares in the last quarter. Russell Investments Group Ltd. boosted its position in Merck & by 2.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 4,206,648 shares of the company’s stock worth $269,678,000 after purchasing an additional 107,201 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH boosted its position in Merck & by 41.9% in the 2nd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 296,294 shares of the company’s stock worth $19,028,000 after purchasing an additional 87,443 shares in the last quarter. Stevens Capital Management LP purchased a new stake in Merck & in the 1st quarter worth approximately $15,126,000. Finally, Trust Co boosted its position in Merck & by 2.8% in the 1st quarter. Trust Co now owns 68,789 shares of the company’s stock worth $4,371,000 after purchasing an additional 1,852 shares in the last quarter. Hedge funds and other institutional investors own 72.84% of the company’s stock.
In related news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.25% of the stock is owned by corporate insiders.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Get a free copy of the Zacks research report on Merck & (MRK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.